Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Esperion Therapeutics Q3 EPS $(0.16) Misses $(0.08) Estimate, Sales $87.309M Beat $77.803M Estimate

Author: Benzinga Newsdesk | November 06, 2025 06:01am
Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.08) by 102.53 percent. This is a 6.67 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $87.309 million which beat the analyst consensus estimate of $77.803 million by 12.22 percent. This is a 69.10 percent increase over sales of $51.632 million the same period last year.

Posted In: ESPR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist